Key statistics dashboard for BridgeBio Pharma, Inc. (BBIO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Stock Data
| Price | $66.14 |
| Market Cap | $13.0B |
| Enterprise Value | $14.77B |
| Beta | 1.09 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -18.47 |
| Price / Book | -5.15 |
| P/S | 18.72 |
| EV/EBITDA | -24.50 |
| EV/Sales | 21.35 |
| EV/FCF | -33.58 |
| P/FCF | -29.45 |
| Earnings Yield | -5.38% |
| FCF Yield | -3.40% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 93.14% |
| EBIT Margin | -89.09% |
| EBITDA Margin | -87.13% |
| Operating Margin | -78.56% |
| Net Margin | -100.64% |
| Return on Equity | 31.67% |
| Return on Assets | -57.20% |
| Return on Invested Capital | -61.77% |
| Return on Capital Employed | -166.38% |
Financial Health
| Current Ratio | 1.23 |
| Quick Ratio | 1.17 |
| Cash Ratio | 0.76 |
| Debt / Equity | -0.99 |
| Debt / Assets | 204.86% |
| Net Debt / EBITDA | -3.01 |
| Interest Coverage | -6.05 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.58 |
Per-Share Data
| Revenue per share | 3.53 |
| Book Value per share | -12.80 |
| Cash per share | 3.68 |
| FCF per share | -2.25 |
| Tangible Book Value per share | -12.94 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 24 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 27 |
| Avg rating (1-5) | 0.89 |
Related companies: ASND · BMRN · EXEL · IONS · JAZZ · MRNA · RNA
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks